Peptic ulcer disease in the 1990s: An Asian perspective

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 6, 1997, Pages

  Fock, Kwong Ming ^a  

^a New Changi Hospital   (Singapore)

Author keywords

associated peptic ulcer; Helicobacter pylori; NSAID; peptic ulcer disease in the elderly

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; AMOXICILLIN; BISMUTH; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; SCLEROSING AGENT;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC THERAPY; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HEMOSTASIS; HUMAN; META ANALYSIS; NEODYMIUM LASER; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; TREATMENT OUTCOME; ULCER HEALING;

EID: 0009645836     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00454.x     Document Type: Review

References (64)

1. Nakamura Y, Kobayashi M, Nagai M et al. A case-control study of ulcerative colitis in Japan. J. Clin. Gastroenterol. 1994; 18: 72-9.
2. Tan CC, Kang JY, Guan R et al. Inflammatory Bowel Disease: An uncommon problem in Singapore. J. Gastroenterol. Hepatol. 1992; 7: 360-2.
3. Robert CSJ, Mayberry IF, Mann R. Inflammatory Bowel Disease in the rural Indian subcontinent: A survey of patients attending mission hospital. Digestion 1990; 47: 42-6.
4. Kang JY, Tay HH, Yap I, Guan R, Lim KP, Math MV. Low frequency of endoscopic oesophagitis in Asian patients. J. Clin. Gastroenterol. 1993; 16: 70-3.
5. Grossman RA, Beneson MW, Scott RM, Snitbhan R, Top FH Jr, Pantuwatana S. An epidemiological study of hepatitis B virus in Bangkok, Thailand. Am. J. Epidemiol. 1975; 101: 144-59.
6. Chen DS, Kuo GC, Sung JL et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: The Taiwan experience. J. Infect. Dis. 1990; 162: 817-22.
7. Parkin DM, Stjernsward J, Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull. World Health Organ. 1984; 62: 163-82.
8. Kang JY, Yap I, Gwee KA. The pattern of functional and organic disorders in an Asian gastrointestinal clinic. J. Gastroenterol. Hepatol. 1994; 9: 124-7.
9. Bloom BS. Cross-national changes in the effects of peptic ulcer disease. Ann. Intern. Med. 1991; 114: 558-62.
10. Kurata JH, Harte BM, Elashoff JD. Sex differences in peptic ulcer disease. Gastroenterology 1985; 86: 88-96.
11. Koo J, Ngan YK, Lau SK. Trends in hospital admission, perforation and mortality of peptic ulcer in Hong Kong from 1970 to 1980. Gastroenterology 1983; 84: 1558-61.
12. Kang JY. Mortality from peptic ulcer in Singapore 1938-1980. Singapore Med. J. 1993; 24: 333-5.
13. Sonneberg A. Changes in physician visits for gastric and duodenal ulcer in the United States during 1958-1984 as shown by National Disease and Therapeutic Index (NDTI). Dig. Dis. Sci. 1987; 32: 1-7.
14. Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment. Pharmacol. Ther. 1955; 9 (Suppl. 2): 59-69.
15. Cullen DJE, Collins DBJ, Christiansen KJ et al. When is Helicobacter pylori infection acquired? Gut 1993; 34: 1681-2.
16. Banatvala N, Mayo K, Mergrand F, Jennings R, Decks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J. Infect. Dis. 1993; 168: 219-21.
17. Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Taupe RV. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 1992; 102: 41-6.
18. Asaka M, Kimura T, Kudo M et al. Relationship of Helicobacter pylori to serum pepsinogen in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760-6.
19. Well J, Collin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br. Med. J. 1995; 310: 827-30.
20. Sommerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; 1: 462-4.
21. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-32.
22. Borody TJ, George LL, Brandl S et al. Helicobacter pylori negative duodenal ulcer. Am. J. Gastroenterol. 1991; 86: 1154-7.
23. Kuipers EJ, Thijs JZ, Festein HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment. Pharmacol. Ther. 1995; 9 (Suppl. 2): 59-69.
24. Rauws EAJ, Tytgat GNJ. Campylobacter. PhD Thesis, Academic Medical Centre, Department of Gastroenterology Amsterdam.
25. Leung KM, Hui PK, Chan WY, Thomas TMM. Helicobacter pylori - related gastritis and gastric ulcer. Am. J. Clin. Pathol. 1992; 98: 569-74.
26. Marshal BJ. Helicobacter pylori. Arn. J. Gastroenterol. 1994; 89: S116-28.
27. Crabtree JE, Taylor JD, Wyatt JI et al. Mucosal IgA recognition of Helicobacter pylori 120 KDa protein, peptic ulceration and gastric pathology. Lancet 1991; 338: 332-5.
28. Xiang Z, Bugnoli M, Rappuoli R, Covacci A, Pouzeetlo A, Crabtree JE. Helicobacter pylori - host responses in peptic ulceration. Lancet 1993; 341: 900-1.
29. Xiang Z, Censius S, Bayeli PF et al. Analysis of expression of Cag A and Vac A virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into major type and that Cag A is not necessary for expression of the vacuolating cytotoxin. Infect. Immun. 1995; 63: 94-8.
30. Figura N. Role of cytotoxin in the pathogenesis of Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol. 1993; 5 (Suppl. 2): S16-8.
31. Telford JL, Ghiara P, Dell'orco M et al. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J. Exp. Med. 1994; 179: 1653-8.
32. Goossens H, Glupczynski Y, Burette A. The role of the vacuolating toxin from Helicobacter pylori in the pathogenesis of duodenal and gastric ulcer. Med. Microbiol. 1992; 1: 153-9.
33. Martin DF, Mortgomery Z, Dobeck AS, Patrissi GA, Peura DA. Campylobacter pylori, NSAIDs and smoking: Risk factors for peptic ulcer disease. Am. J. Gastroenterol. 1989; 84: 1268-72.
34. Blaser MJ, Chyon PH, Nomura A. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer and duodenal ulcer risk. Cancer Res. 1995; 55: 562-5.
35. Hosking SW, Yung MY, Chung SC, Li AKC. Differing prevalence of Helicobacter in bleeding and non-bleeding ulcers. Gastroenterology 1992; 102: A85.
36. Ng TM, Fock KM, Khor JL et al. Helicobacter pylori and NSAIDs in bleeding gastric ulcer. Gastroenterology 1996; 110: A12.
37. Reinbach DH, Cruickshank G, McColl KEL. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection. Gut 1993; 34: 1344-7.
38. Veldhuyzen van Zanten SOJ. H. pylon and NSAID's: A meta-analysis on interactions of acute gastroduodenal injury, gastric and duodenal ulcers and upper gastrointestinal symptoms. In: Hunt RH, Tytgat GNJ eds. Helicobacter pylori. Basic mechanism to clinical cure. Dudrecht, Netherlands: Kluwar Academic, 1994; 449-57.
39. Hawkey CJ. Future treatments for arthritis: New NSAIDs, No NSAIDs or No No NSAIDs. Gastroenterology 1995; 109: 614-616
40. Hawkey CJ. Non-steroidal anti-inflammatory drugs and ulcers: Facts and figures multiply, but do they add up? Br. Med. J. 1990; 300: 278-84.
41. Henry D, Robertson J. Non-steroidal anti-inflammatory drugs and peptic ulcers hospitalization rates in New South Wales. Gastroenterology 1993; 104: 1083-91.
42. Silverstein FE, Geis GS, Stramers BJ et al. NSAIDs and gastrointestinal injury: Clinical outcome, the mucosa trial (abstract). Gastroenterology 1994; 106: A180.
43. Bellary SV, Isaacs PET, Lee FI. Upper gastrointestinal lesions in elderly patients presenting for endosocpy: Relevance of NSAID usage. Am. J. Gastroenterol. 1991; 86: 961-4.
44. Weil J, Colin-Jones D, Langman MIS et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br. Med. J. 1995; 30: 827-30.
45. Langman MJS, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.
46. Population Report 1994. Singapore: Population Manning Unit, Ministry of Health, 1995.
47. Ng TM, Fock KM, Chia SC et al. Peptic ulcer disease in the elderly in Singapore. J. Gastroenterol. Hepatol. 1994; 9: 278-81.
48. Gilbert DA. Epidemiology of upper gastrointestinal bleeding. Gastrointest. Endosc. 1990; 36: S8-13.
49. Consensus Development Panel. Consensus statement on therapeutic endoscopy and bleeding ulcers. Gastrointest. Endosc. 1990; 36: S62-5.
50. Chung SCS, Leung JWC, Steela RJC, Crofts TJ, Li AKC. Endoscopic injection of adrenaline for actively bleeding ulcers: A randomised trial. Br. Med. J. 1988; 296: 1631-3.
51. Fock KM, Ng TM, Chong YY, Chia SC, Chew CN. Endoscopic adrenaline injection in treatment of bleeding peptic ulcers. Int. Surg. 1995; 80: 134-7.
52. Cook DJ, Guyart GH, Salena BJ, Laine L. Endoscopic therapy for acute variceal upper gastrointestinal haemorrhage: A meta-analysis. Gastroenterology 1992; 102: 139-48.
53. Chen TS, Tsay SH, Chang FV, Li SD. Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: Comparison of 1 week and 2 week regimens and recrudescence rates over 12 months. J. Gastroenterol. Hepatol. 1995; 10: 330-5.
54. Unge P. Review of Helicobacter pylori eradication regimens. Scand. J. Gastroenterol. 1996; 31 (Suppl. 215): 74-81.
55. Rautelin H, Seppala K, Renkonen O-V, Vainio U, Kosunen TU. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob. Agents Chemother. 1992; 36: 163-6.
56. Moayyedi P, Sahay P, Tompkins DS, Axon ATR. Efficacy and optimum dose of omeprazole in a new one week triple therapy regimen to eradicate Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. 1995; 7: 9-11.
57. Ching CK, Lam SK, Yung RWH et al. Prevalence of metronidazole resistant Helicobacter pylori (Hp) strains among the Chinese peptic ulcer disease patients and normals in Hong Kong. Gastroenterology 1995; 109: A965.
58. Ng TM, Fock KM, Sim CS et al. Helicobacter pylori infection in duodenal ulcer of an urban population in the Asia-Pacific region. Am. J. Gastroenterol. 1994; 89: A444.
59. Ayyagaii A, Sharma S, Prasad KW et al. Metronidazole resistant Helicobacter pylori in India. Am. J. Gastroenterol. 1994; 89: A314.
60. Agrawal NM, Dajani EZ. Prevention and treatment of ulcers induced by non-steroidal anti-inflammatory drugs. J. Assoc. Acad. Minor Phys. 1992; 3: 142-8.
61. Pipkin G, Mills JG. Treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal damage. Efficacy of anti-secretory and mucosal protective compounds. Dig. Dis. 1995; 13 (Suppl.): 75-88.
62. Hollander D. Gastrointestinal complications of non-steroidal anti-inflammatory drugs: Prophylactic and therapeutic strategies. Am. J. Med. 1994; 96: 274-81.
63. Agrawal NM. Epidemiology and prevention of non-steroidal anti-inflammatory drug effects in the gastrointestinal tract. Br. J. Rheumatol. 1995; 34 (Suppl. 1): 5-10.
64. Grazioli I, Avossa M, Boglio IOA et al. Multicentre study of the safety/efficacy of misoprostol in the prevention and treatment of NSAID induced gastroduodenal lesions. Clin. Exp. Rheumatol. 1993; 11: 289-94.